Together with the previous study showing that GSK-3β inhibition suppressed NF-κB transcriptional activity in U2OS osteosarcoma cells [25], these results suggest that GSK-3β participates in osteosarcoma cell survival by activation of NF-κB and inactivation of the β-catenin osteosarcoma suppressor, in the context of cancer cell types with different genetic and molecular characteristics. The gene discussed is GSK3B; the disease is osteosarcoma.